Company intelligence / Profile preview

LinqMed

Chuo-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

LinqMed’s lead radiotherapeutic, 64Cu–ATSM, selectively accumulates in hypoxic tumor cells and is currently in Phase III clinical trials for malignant brain tumors. The company is pioneering the use of copper radioisotope 64Cu to combine diagnosis and therapy (“Visible Cancer Therapeutics”) on a single platform. Early results suggest high selectivity for hypoxic cancer cells with potential to address treatment-resistant cancers such as glioblastoma. The company has received recognition from major Japanese innovation programs and has secured Series A funding.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall moleculePeptidesAntibody
Industry: Biotech

Drug pipeline

1 asset

copper-64-diacetyl-bis(N4-methylthiosemicarbazone)

Partnerships

PDRadiopharma Inc. (strategic manufacturing/distribution partnership in Japan)

Beyond the preview

Go deeper on LinqMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LinqMed.

Explore the full profile